Jacobs Levy Equity Management, Inc Assembly Biosciences, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.13 - $3.46 $427,177 - $693,913	-200,553 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $62,630 - $77,789	-19,946 Reduced 9.05%	200,553 $698,000
Q2 2021 Aug 16, 2021	SELL	$3.8 - $4.56 $138,380 - $166,056	-36,416 Reduced 14.17%	220,499 $856,000
Q1 2021 May 17, 2021	BUY	$4.33 - $6.63 $363,581 - $556,707	83,968 Added 48.55%	256,915 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$4.87 - $17.29 $842,251 - $2.99 Million	172,947 New	172,947 $1.05 Million
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $192,439 - $397,807	-18,738 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $44,876 - $127,812	5,368 Added 40.15%	18,738 $383,000
Q3 2019 Nov 14, 2019	BUY	$9.83 - $14.82 $131,427 - $198,143	13,370 New	13,370 $131,000
Q4 2017 Feb 13, 2018	SELL	$28.58 - $49.91 $559,653 - $977,337	-19,582 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$23.08 - $34.92 $532,824 - $806,163	-23,086 Reduced 54.11%	19,582 $684,000
Q2 2017 Nov 09, 2017	BUY	N/A	42,668	42,668 $881,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.